The FDA on March 31, 2017 granted regular approval to IBRANCE® for the treatment of Hormone Receptor (HR) positive, Human Epidermal growth factor Receptor 2 (HER2) negative advanced or metastatic breast cancer, in combination with an Aromatase Inhibitor, as initial endocrine based therapy in postmenopausal women. IBRANCE® is marketed by Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
